Overview

Study of NNZ-2566 in Patients With Traumatic Brain Injury Under EFIC

Status:
Completed
Trial end date:
2016-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether NNZ-2566 is safe and effective in the treatment of Traumatic Brain Injury (TBI).
Phase:
Phase 2
Details
Lead Sponsor:
Neuren Pharmaceuticals Limited